Phoenix Biotech Acquisition Corp. Unit
PBAXU
PBAXU was delisted on the 7th of February, 2024.
2 hedge funds and large institutions have $1.07M invested in Phoenix Biotech Acquisition Corp. Unit in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
6% less capital invested
Capital invested by funds: $1.14M → $1.07M (-$67K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
-$104K |
PBAXU Hedge Fund Activity: Q1 2023 in Review
2 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q1 2023, worth a combined $1.07M — down 5.9% from $1.14M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PBAXU and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Flow Traders U.S., exiting entirely with an estimated $104K sold.
- 2 institutional investors held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q1 2023, down from 3 in Q4 2022.
- Funds reported $1.07M of Phoenix Biotech Acquisition Corp. Unit stock for Q1 2023, down 5.9% quarter-over-quarter.
- 0 funds opened new Phoenix Biotech Acquisition Corp. Unit positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest Phoenix Biotech Acquisition Corp. Unit seller in Q1 2023 was Flow Traders U.S., an estimated $104K sold.
Based on aggregated 13F filings for Q1 2023.